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Abstract
Background: Since mitochondria are the principal source of reactive oxygen species (ROS), these organelles may play an
important role in ischemic cardiomyopathy (IC) development. The mitochondrial genome may influence this disease. The
aim of the present study was to test the relationship between IC development and the impact of single nucleotide
polymorphisms (SNPs) in mitochondrial DNA (mtDNA) defining the mitochondrial haplogroups in a population study.
Methodology and principal findings: Ten major European haplogroups were identified by using the single base extension
technique and by polymerase chain reaction-restriction fragment length polymorphism. Frequencies and Odds Ratios for
the association between IC patients (n = 358) and healthy controls (n = 423) were calculated. No convincing associations
between classical risk factors for ischemic cardiomyopathy development and haplogroups were found. However, compared
to healthy controls, the prevalence of haplogroup H was significantly higher in IC patients (40.0% vs 50.0%, p-value = 0.039)
while the frequency of haplogroup J was significantly lower (11.1% vs 5.6%, p-value = 0.048). The analysis of the SNPs
characterizing the European mtDNA haplogroups showed that the m.7028C allele (40.0% vs 50.0%, p-value = 0.005) and
m.14766C allele (43.0% vs 54.2%, p-value = 0.002) were overrepresented in IC patients, meanwhile the m.10398G allele
(19.8% vs 13.1%, p-value = 0.015) and m.4216C allele (22.2% vs 16.5%, p-value = 0.044) were found as protective factors
against IC.
Conclusions and significance: Our results showed that the haplogroups H and J were found as a risk and protective factors
for ischemic cardiomyopathy development, respectively.
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Introduction
Ischemic heart failure continues to be a major health problem in
the Western countries [1]. An in-depth understanding of its basic
pathophysiological mechanisms is necessary to provide early
prognosis and better therapies for preventing and prevention of
the disease. It is generally known that reactive oxygen species
(ROS) are involved in various cardiovascular diseases, such as
ischemic injury, coronary heart disease and congestive heart
failure. An imbalance between endogenous oxidants and anti-
oxidants results in oxidative stress, which contributes to vascular
dysfunction and atherogenesis [2]. Atherosclerosis in coronary
arteries is the primary cause of ischemic cardiomyopathy (IC).
Inflammation and ROS production have recently been established
as key mechanisms in the pathogenesis of atherosclerosis and in
coronary artery disease progression [3,4]. Because mitochondria
are the principal source of ROS in cardiomyocytes, these
organelles may play an important role in ischemic cardiomyopathy
development.
Human mitochondrial DNA (mtDNA) encodes 37 genes. Yet,
only 13 of these genes are transcripted into 13 polypeptides. They
constitute essential subunits of the mitochondrial oxidative
phosphorylation enzymatic complexes that generate the main
source of ATP [5,6]. The mtDNA mutations accumulated
throughout human history have divided human populations into
a small number of mitochondrial haplogroups. Point mutations
observed in over 1% in the population are known as SNP (Single
Nucleotide Polymorphism). A mitochondrial haplogroup is defined as
a collection of haplotypes characterized by specific SNPs [7].
Haplogroups exhibit specific polymorphisms in indigenous
populations and this phenomenon has been attributed to genetic
drift and/or possible climate selection [8,9].
Although polymorphic variants are not pathogenic, they are not
silent either. For example, specific mitochondrial polymorphisms
are involved in the assembly of components of the mitochondrial
respiratory chain [10]. Moreover, several studies have shown
mitochondrial haplogroups to be associated with differences in the
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amount of superoxide and other ROS produced by the electron
transport chain [11]. Consequently, this leads to varying amounts
of oxidative stress in cells depending upon their haplogroup and
therefore to differences in morbidity, mortality and longevity
amongst individuals with distinct haplogroups [12,13]. One study
has reported that individuals with haplogroup J present lower
oxygen consumption than other haplogroup variants [11]. This
could be due to decreased efficiency of their electronic respiratory
chain and therefore, a decreased in ATP and ROS production [9].
Thus, specific haplogroups may constitute either a risk or
a protective factor in the origin of complex diseases and age-
related diseases such as Parkinson`s [14], Alzheimer`s disease
[15,16], osteoarthritis [17,18] and several cancers [19,20].
Mitochondrial haplogroups have also been associated with in-
creased risk of developing various cardiovascular diseases. For
example, haplogroup T has been found more frequent in patients
with hypertrophic cardiomyopathy [21]. Whilst haplogroup H1
[22], K [23], the Asian haplogroup N9b [24] have been reported
as protective factors against ischemic stroke, the Asian hap-
logroups A and M7a confer a genetic risk for developing coronary
atherosclerosis [25]. Conversely, it is worth noting that a large
population study did not find any association between mtDNA
haplogroups and ischemic heart disease in a European population
[26].
The differences in mitochondrial energetic production among
haplogroups could potentially affect the development of IC. This
study was designed to investigate the possible association of
mitochondrial haplogroups in a population of 358 IC patients and
423 controls from the Spanish population. To accomplish this, we
genotyped both groups of individuals for the most common
European haplogroups and examined the differences in their
frequency between controls and IC patients.
Methods
Ethics Statement
The study was conducted according to the Spanish Law for
Biomedical Research (Law 14/2007-3 of July) and complied with
the Declaration of Helsinki. The study and the use of archive
samples for this project were approved by the Research Ethics
Committee of Galicia. The National DNA Bank, which provided
DNA samples, received the approval from their own ethical
committee. Written informed consent was obtained from all
patients. All the samples were collected anonymously.
Patients and Controls
This case-control followed STREGA guidelines [27]. DNA
samples from 781 unrelated Spanish individuals (423 healthy
controls and 358 IC patients) were analysed in this study. The
ischemic cardiopathy group included 225 patients obtained from
A Corun˜a University Hospital Cardiology Unit and 133 provided
by the National DNA Bank (University of Salamanca, Spain). The
control group was an age and sex matched population of donors
from A Corun˜a University Hospital Blood Bank. Individuals in
this group represented both genders and had no history of IC.
Ischemic cardiopathy was defined according to the American
College of Cardiology and American Heart Association clinical
standards [28]. Information about known ischemic cardiopathy
risks was collected. Hypercholesterolemia was considered a risk if
total cholesterol levels $220 mg/dl. Hypertension was defined as
systolic blood pressure $140 mm Hg, diastolic blood pressure
$90 mm Hg or by the use of antihypertensive medication.
Diabetes mellitus was defined as a self-reported disease, use of
antidiabetic drugs, or a nonfasting plasma glucose $11 mmol/l.
Smokers were defined as current smokers.
Assignment of mtDNA Haplogroups
Haplogroup analysis was performed taking into account a pre-
viously described protocol [18]. This strategy was based on the use
of single base extension (SBE) for the assessment of European
mtDNA haplogroups. The SBE assay allows identifying six SNPs
that determine the most frequent European haplogroups (H, T, K,
U, J, V), while the less common haplogroups (W, I, X and HV)
were identified afterwards by polymerase chain reaction-restriction
fragment length polymorphisms (PCR-RFLPs).
Total DNA was extracted from blood samples using QIAmp
DNA Blood Mini Kit (Qiagen, Germany). Fragments containing
the six target SNPs were amplified using twelve primers listed in
Table 1. The multiplex PCR mixture was diluted in Reaction
Buffer (Bioline, UK) on a final concentration of 0.2 mM of each
deoxynucleotide (dNTP) (Bioline. UK), 1.5 mM MgCl2 (Bioline,
UK), 0.025 U/ml of Bio Taq DNA polymerase (Bioline, UK) and
0.3 mM of each primer in a total volume of 25 ml. Isolated DNA
(100 ng) was added to the mixture and amplified at 94uC for
5 minutes, 35 cycles at 95uC for 60 seconds, 55uC for 60 seconds
and 72uC for 60 seconds, with a final extension at 70uC for
10 minutes. 1.5 ml of PCR products were treated with 0.6 ml
ExoSap-It (Amersham, UK) followed by an activation of the
enzyme at 37uC for 15 minutes and a further deactivation by
incubation at 80uC for 15 minutes. Samples were stored at 4uC.
The SBE assay consisted on annealing of 6 single primers to 6
fragments amplified with Multiplex PCR (Table 1). The 39 end of
each primer was one base shorter of the SNP site of interest. Only
dideoxynucleotides (ddNTPs) were employed in the reaction.
When the complementary base was incorporated by the Taq DNA
polymerase, the elongation stops and the SNP site were marked.
Multiplex SBE reactions were performed by adding 1.5 ml of
SNaPshotH Multiplex kit (Applied biosystems, EEUU), 2.1 ml of
purified PCR product and of 0.2 mM of SBE primers mixture
(Table 1). Reaction volumes were adjusted to 10 ml using ddH2O.
Thermal cycling for SBE was 96uC for 60 seconds and 25 cycles at
96uC for 20 seconds, 60uC for 5 seconds and 60uC for 30 seconds.
To dispose ddNTPs, the SBE reaction products (10 ml) were
treated with 1 ml of Shrimp Alkaline Phosphatase (SAP) and 2 ml
of SAP Reaction Buffer (Amersham, UK). Reaction volumes were
adjusted to 20 ml using ddH2O. The mixture was incubated at
37uC for 1 hour and SAP was inactivated in a final incubation at
75uC for 15 minutes. Samples were stored at 4uC.
Finally, 9 ml of Hi-DiTM Formamide (Applied Biosystems,
EEUU), 0.5 ml of internal size standard (120 Liz Size; Aplied
Biosystems, USA) and 0.5 ml of purified SBE product were mixed
and denatured at 95uC for 5 minutes before loading into and ABI
3130XL genetic analyzer. The system configuration is based on
a 36 cm length capillary tube filled with Performance Optimized
Polymer 4 (Applied Biosystems, USA) containing urea. The
default SBE run module was 22 seconds of injection time,
16 minutes of running time and a running voltage of 15KVolts.
Once the runs finished, the data were analyzed using GeneMap-
per v3.5 software (Aplied Byosistems, USA). This software assigns
the different SNPs in each locus prior to the designing of
a reference sequence encompassing all the allelic variants for each
locus.
The PCR-RFLP assay was performed on those samples having
no haplogroup assigned after the SBE assay. The samples were
amplified with the corresponding primers (Table 1) and digested
depending on the nucleotide localised at polymorphic site 10398
(m.10398A.G). Samples with the m.10398G allele were tested for
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10032AluI (10032 AluI positive samples were assigned to
haplogroup I (m.10034C allele), and 10032 AluI negative samples
were assigned to ‘‘others’’). Samples having m.10398A allele were
tested for 14465AccI and 8994HaeIII. 14465AccI positive samples
were assigned to haplogroup X (m.14470C allele). 14465AccI
negative (m.14470T allele) and 8994HaeIII negative (m.8994A
allele) samples were assigned to haplogroup W. 10–15 ml of PCR
product were digested with 2 ml of the appropriate restriction
enzyme (Table 1), 4 ml of buffer and ddH2O to reach a final
volume of 40 ml. Digestion was performed at 37uC for 90 minutes.
Then, the samples were stored at 4uC. To confirm that the enzyme
indeed cut the amplified fragment, the digestion products were run
in agarose gels and visualized using UV after SYBR-safe
treatment.
Statistical Methods
Data were analyzed using SPSS 17.0 software (IBM, USA).
Haplogroup and allele frequencies in patients and controls were
compared using the chi-square test from contingency tables. The
Odds Ratio (OR) and 95% confidence intervals (CI) were
calculated for each haplogroup. For the haplogroup analysis, each
haplogroup was compared against all the other haplogroups
pooled into a single group. The less frequent haplogroups I, W and
X, which account for less than 10 controls/patients, were re-
grouped based on common-ancestor criteria. The haplogroup HV
was re-grouped as ‘‘others’’. Binary logistic regression adjustment
was used to test the influence of hypercholesterolemia, hyperten-
sion, diabetes mellitus and the smoking habit. Differences were
considered significant when p,0.05 (2-tailed test). The Bonferroni
correction for multiple comparisons was applied. Thus, p-values
Table 1. Primer sequences used for in multiplex PCR, SBE and PCR-RFLP.
Polimorphic
site PCR primer Position
SNP
analyzed
Restriction
enzime
Multiplex
PCR
7028 59-CTGACTGGCATTGTATTAGCA-39 59-
GTATACGGGTTCTTCGAATG-39
6960F 7433R
14766 59-GAGAAGGCTTAGAAGAAAACCCCAC-39 59-
GTGGGCGATTGATGAAAAGGC-39
14601F 14950R
10398 59-GGCCTATGAGTGAACTACAAAA-39 59-
TATTCCTAGAAGTGAGATGGT-39
10364F 10526R
4580 59-CCTACCACTCACCCTAGCATTAC-39 59-
TAGGAATGCGGTAGTAGTTAG-39
4185F 5120R
12308 59-CAACCCCGACATCATTACCGGGT-39 59-
GGGTTAACGAGGGTGGTAAGG-39
12106F 12413R
4216 59-CCTACCACTCACCCTAGCATTAC-39 59-
GCGAGCTTAGCGCTGTGATGAG-39
4185F 4542R
Single
Base
Extensi
on (SBE)
7028 59-ACACGACACGTAACTACGTTGTAGC-39 7004F m.7028C.T
14766 59cgatcATGAGTGGTTAATTAATTTTATTAGGGTTA-39 14798R m.14766C.T
10398 59-ataTATGAGTGACTACAAAAAGGATTAGA CTGA-39 10368F m.10398A.G
4580 59-(at)7TTTTTTACCTGAGTAGGCCTAGAAA TAAACAT-39 4548F m.4580G.A
12308 59-(tacg)5aCCATTGGTCTTAGGCCCCAA-39 12288F m.12308A.G
4216 59-cgCCACTCACCCTAGCATTACTTATATG A-39 4189F m.4216T.C
PCR-
RFLP
10032 59-CTTTGGCTTCGAAGCCGCCGCC-39 59-
TATTCCTAGAAGTGAGATGGT-39
9902F 10526R m.10034T.C (2)AluI
14465 59-ATGCCTCAGGATACTCCTCAATAGCCAT C- 39 59-
CCGTGCGAGAATAATGATGTATGC-39
14430F 14686R m.1470T.C (+)AccI
8994 59- TAGCCCACTTCTTACCACAAGGC-39 59-
GTGTGAAAACGTAGGCTTG-39
8900F 9172R m.8994G.A (2)HaeIII
R: primer in reverse orientation; F:primer in forward orientation.
*Lower case letters indicate the unspecific nucleotides in 59-end of the SBE primer. PCR products for RFLP analysis were digested with the corresponding restriction
enzyme and digested PCR products appeared like three fragments in agarose gel.
doi:10.1371/journal.pone.0044128.t001
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were multiplied by the number of outcomes (k = 8 for mtDNA
haplogroups and k = 4 for mtDNA clusters) tested.
Haplogroups prevalence varies extremely, with frequencies
between 40% to ,5% in the general population. Assuming
a haplogroup prevalence of 40% in the control group, the sample
size of this study provides 80% power to detect a significant
associated odds ratio $1.50, at 2-sides significant level of 0.05. For
a haplogroup with prevalence around 20%, the sample size allows
to detect significant odds ratios $1.64 (power = 80%, a level of
0.05). For more rare haplogroups (prevalence around 5%), only
odds ratios $ 2.27 will be detected as statistically significant
(power = 80%, a level of 0.05).
Results
No Association was Found between Mitochondrial
Haplogroups and the Major Risk Factors for IC
Of the 781 Spanish subjects included in this study, 358 had been
previously diagnosed with IC (case group) and 423 were controls
with no history of IC. Because IC is a very common late-onset
disease we chose subjects of similar ages in both groups (66.3611.8
years for the IC group and 66.5611.9 years for the control group).
The lower proportion of women developing IC was also
considered. For this, the control group (17.5% of women) was
selected to have frequency similar to the case group (18.2% of
women). Risk factors for ischemic cardiovascular events stratified
by mitochondrial haplogroups are listed in Table S1. Remarkably,
the distribution of haplogroups for the major IC risk factors was no
different between controls and patients.
Haplogroups H and J were Respectively, Risk and
Protective Factors for IC
Study subjects were genotyped for the most common European
descent mitochondrial haplogroups; the resulting frequencies are
shown in Table 2. The frequencies obtained ranged from 50.0%
for the most common haplogroup H, to 0.8% for the less prevalent
haplogroup I. The haplogroup frequencies for our controls did not
differ substantially from those reported in previous studies on
different European populations (Table S2) [29–31]. Using the
rapid and effective multiplex SBE assay, 89.88% of the samples
were assigned to the most common European mtDNA hap-
logroups (H, U, J, K, T, V). The less frequent haplogroups (X, I,
W) were determined for 6.02% of the samples using the classical
PCR-RFLP assay. Only 4.10% of the samples remained un-
determined after the analysis and they were classified as ‘‘others’’.
The frequencies of two mitochondrial haplogroups in IC
patients differed significantly from those in healthy controls. The
haplogroup H was significantly overrepresented in IC patients
(OR = 1.50 CI = [1.13–2.00], p,0.05) when each haplogroup was
compared against the remaining pooled haplogroups. (Table 2).
On the other hand, the frequency of haplogroup J in IC patients
was significantly lower than in controls (OR = 0.47 CI = [0.28–
0.82], p,0.05). These results suggest that haplogroup H
constitutes a risk factor while haplogroup J is a protective factor
for IC.
Hypercholesterolemia, hypertension, diabetes and smoking
habit were significantly independently associated with IC after
the multivariate logistic regression analysis (Table 3). Our results
supported previous studies showing that IC development was
associated with hypercholesterolemia (OR = 1.58 CI = [1.13–
2.20], p,0.05), hypertension (OR = 2.01 CI = [1.46–2.76],
p,0.001), diabetes (OR = 1.58 CI = [1.09–2.28], p,0.05) and
cigarette smoking (OR = 2.37 CI = [1.63–3.45], p,0.001). The
haplogroup H continued to be a risk factor compared with
haplogroup J (OR = 0.28 CI = [0.15–0.52], p,0.001) and others
(OR = 0.59 CI = [0.37–0.95] p,0.05) (Table 3). These results
support the conclusion that patients with IC are overrepresented
in haplogroup H compared with the haplogroup J and others.
Because the analyzed haplogroups share a common ancestor
and several SNPs have been conserved during evolution, in our
study we also examined the frequencies of clusters HV, JT, KU
and IWX. Although the frequency of haplogroup J was found to
be significantly different from controls, no difference was found in
Cluster JT between controls and patients with IC (Table 2).
However, cluster HV was found to be a risk factor for IC
(OR = 1.47 CI = [1.11–1.96], p,0.05).
The analysis of the SNPs characteristic of the European
mtDNA haplogroups showed that frequency of the C allele at
positions 7028 and 14766 was significantly higher in patients with
IC (OR = 1.50 CI = [1.13–2.00], p,0.05 and OR = 1.57
CI = [1.18–2.08], p,0.05) respectively). The nucleotide change
in 7028 locus causes a synonymous amino acid change whilst 14766
locus produces a non-synonymous amino acid change in cyto-
chrome b (p.Thr7Ile). On the other hand, the m. 10398G allele
and the m.4216C allele were found as protective factors against IC
(OR = 0.61 CI = [0.41–0.91], p,0.05 and OR = 0.69 CI = [0.48–
0.99], p,0.05, respectively). The SNP m.10398A.G causes
a non-synonymous amino acid change in NADH dehydrogenase
subunit 3 (p.Thr114Ile) which is observed in haplogroups K, J and
I. The SNP m.4216T.C is specific for the cluster JT and
produces a non-synonymous amino acid change in NADH
dehydrogenase subunit 1 (p.Tyr304His).
Discussion
We found significant associations of mitochondrial haplogroups
H and J and the incidence of ischemic cardiomyopathy in
a Spanish population. Our results showed that the haplogroups H
and J are respectively risk and protective factors for ischemic
cardiomyopathy development.
In our study population, age and gender proportions were
similar in the case and control groups. This permitted us to
exclude any bias due to age or gender differences. Also, we
checked the frequencies for major risk factors for ischemic
cardiomyopathy (hypercholesterolemia, hypertension, diabetes
and cigarette smoking) stratified by mitochondrial haplogroups
showing that they were not altered. According to other studies
classical risk factors for IC development were independently
associated with IC [32,33].
Several studies have demonstrated association between hap-
logroups and complex or aged-related diseases, including cardio-
vascular diseases [14–24]. In agreement with our findings, a recent
study showed that mitochondrial haplogroup H is a risk factor for
the early onset myocardial infarction [34]. Besides, Gallardo et al.
described haplogroup H as a risk factor for the progress to end-
stage heart failure in a Spanish population [35]. In agreement with
our study they observed that the frequency of haplogroup H in 174
IC patients was 53% when they divided the allograft recipients
according to aetiology. Our data support in a statistical way that
haplogroup H is a risk factor for ischaemic cardiomyopathy.
Although many SNP characterised haplogroup H, the
m.14766C allele constituted a risk factor for the development of
ischemia in our study. The SNP m.14766C.T causes the amino
acid substitution of a threonine for an isoleucine at site 7 in
cytochrome b, thus possibly affecting protein complex II and the
electron transport chain. A computational approach showed that
the region around cytochrome site 7 is more open, less globular
and less compact due to the presence of a threonine. Consequent-
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ly, the efficiency of the ETC is expected to be higher in
haplogroup H cells [36]. The allele m.7028C, which also
characterizes the haplogroup H, was also found overrepresented
in our study. However, the SNP m.7028C.T causes a synony-
mous amino acid change, therefore this SNP is not responsible of
phenotypic effect that define haplogroup H as a risk factor for IC
development. On the other hand, Rosa et al. reported the sub-
haplogroup H1 as a protective factor for ischemic stroke [22].
Because sub-haplogroup H1 is defined at the 7028 mtDNA
position by the same SNP as haplogroup H, other polymorphisms
present in sub-haplogroup H1 might produce different pheno-
types. A case-controlled study including 920 patients and 522
controls reported haplogroup N9b specific polymorphisms
m.11016G.A (p.Ser86Asn in NADH dehydrogenase 4) and
m.13183A.G (p.Ile283Val in NADH dehydrogenase 5) confer
resistance against ischemic events [24]. The haplogroup J specific
polymorphisms that we report here to be protective factors are not
present in haplogroup N9b. On the contrary, haplogroup J is
characterized by several missense mutations affecting genes
encoding cytochrome b (m.15452C.A), NADH dehydrogenase
1 (m.4216T.C) and NADH dehydrogenase 5 (m.13708G.A). All
these gene products are involved in the oxidative phosphorylation
and ATP production [8,37]. Furthermore, a different study
revealed that the m.295C.T polymorphism of haplogroup J
increases the mtDNA replication in vitro. This polymorphism maps
the mitochondrial transcription factor A binding-site but in-
triguingly, this mtDNA increment could not be associated with an
increment in the mRNA levels of mtDNA-encoded genes [38]. We
suggest that no single specific SNP is responsible for the protective
effect, but it is due to a particular set of polymorphisms in
haplogroup J.
There are several evidences for an association of mtDNA
haplogroups with the ischemic event [25,26,29], but a definitive
conclusion has not been reached yet. Although distribution in our
control population did not differ from those in other European
studies [29–31], an exhaustive work carried by Benn et al. in
a Danish population found no differences between mitochondrial
haplogroups and risk for ischemic cardiovascular disease [26].
Therefore, our Spanish population cannot be directly extrapolated
to other Northern European populations. Also, Kofler et al. found
a higher frequency of haplogroup T among coronary artery
disease patients from Austria [30]. In our work we did not find
differences in the frequency of haplogroup T. These works
emphasize the difficulty of finding reproducible mitochondrial
genome associations with ischemic heart disease. The differing
results of these studies might arise from geographic specificity for
some mtDNA SNPs and clades.
Results emerging from many studies have provided insights
concerning different energy efficiency between haplogroups J and
H. Haplogroup J could have lower oxygen consumption than H
[11,39], with lower efficiency in the electronic respiratory chain
and low ATP and ROS production. Consequently, cells with
mitochondrial haplogroup H undergo more mitochondrial oxida-
tive damage than those carrying the J haplogroup [11]. Because
the heart has the highest oxygen uptake rate in the body, we
Table 2. Frequencies and OR of mitochondrial haplogroups and clusters in controls and patients with IC.
Nu of individuals (%) Total OR [95%CI] p-value
Control
(n = 423)
IC patients
(n = 358)
Haplogroups H 169 (40.0) 179 (50.0) 348 (44.6) 1.50 [1.13–2.00] 0.039*
U 73 (17.3) 58 (16.2) 131 (16.8) 0.92 [0.64–1.35] 0.694
J 47 (11.1) 20 (5.6) 67 (8.6) 0.47 [0.28–0.82] 0.048*
T 47 (11.1) 39 (10.9) 86 (11.0) 0.98 [0.62–1.53] 0.923
K 28 (6.6) 19 (5.3) 47 (6.0) 0.79 [0.43–1.44] 0.442
V 13 (3.1) 10 (2.8) 23 (2.9) 0.82 [0.39–2.09] 0.818
I WX 27 (6.4) 20 (5.6) 47 (6.0) 1.13 [0.60–2.12] 0.698
OTHERS 19 (4.5) 13 (3.6) 32 (4.1) 0.80 [0.39–1.65] 0.551
Clusters HV 188 (44.4) 194 (54.2) 382 (48.9) 1.47 [1.11–1.96] 0.027*
JT 94 (22.2) 59 (16.5) 153 (19.6) 0.69 [0.48–0.99] 0.044
KU 101 (23.9) 77 (21.5) 178 (22.8) 0.88 [0.63–1.23] 0.444
IWX 27 (6.4) 20 (5.6) 41 (6.0) 1.13 [0.60–2.12] 0.698
OR. Odds Ratio. 95%CI. Confidence Intervals. IC. Ischemic cardiomyopathy.
*Bonferroni corrected p-value ,0.05/8 for haplogroups and p-value ,0.05/4 for clusters. Significant differences (p-value,0.05) are indicated in bold.
doi:10.1371/journal.pone.0044128.t002
Table 3. Multivariate analysis of the study groups.
B SEM OR [95% CI] p-value
Hypercholesterolemia 0.458 0.170 1.58 [1.13–2.20] 0.023
Hypertension 0.696 0.163 2.01 [1.46–2.76] 0.000
Diabetes 0.456 0.187 1.58 [1.09–2.28] 0.011
Smoking habit 0.864 0.191 2.37 [1.63–3.45] 0.000
Haplogroup H – – 1 –
Haplogroup U 20.305 0.214 0.74 [0.48–1.12] 0.155
Haplogroup J 21.259 0.310 0.28 [0.15–0.52] 0.000
Haplogroup T 20.298 0.253 0.74 [0.45–1.22] 0.239
Haplogroup K 20.292 0.330 0.75 [0.39–1.42] 0.376
OTHERS 20.519 0.241 0.59 [0.37–0.95] 0.031
B. Regression coefficient. SEM. Standart error of the mean. OR. Odds Ratio.
95%CI. Confidence Intervals.
Significant differences (p-value,0.05) are indicated in bold.
doi:10.1371/journal.pone.0044128.t003
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speculate that minor differences in energy efficiency might lead to
major physiological effects. The present study focuses on in-
vestigating whether differences among haplogroups have con-
sequences for ischemic cardiomyopathy development. Atheroscle-
rosis in coronary arteries is the major cause of ischemic
cardiomyopathy, and it is well established that inflammation is
a key mechanism in the pathogenesis of atherosclerosis [2]. A
persistent or continuously repeated insult leads to chronic
inflammation that results in tissue destruction and organ
dysfunction. ROS production plays a decisive role in tissue
inflammation, and consequently, in atherosclerosis [40]. Endo-
thelial cells, smooth muscle cells and macrophages are sources of
ROS that oxidize low-density lipoprotein (LDL). The passage of
oxidized LDL through the endothelium into the artery wall is the
first step of a cascade that ultimately leads to formation of the
fibrous plaque that protrudes into the arterial lumen and causes
ischemia [41]. Because haplogroup H might produce more ROS
than other haplogroup variants, we suggest that this precipitates
the first steps in this inflammation process. In individuals with
haplogroup H, the high ROS production from cells involved in the
course of inflammation accelerates the catastrophic cycle of
atherothrombosis. Conversely, low ROS production on cells with
haplogroup J might produce the opposite effect.
It is clear that both aetiology and pathology of ischemic
cardiomyopathy are complex, and the mitochondrion plays
a critical role in this process. Mitochondrial haplogroups may
act synergistically with other nuclear genetic factors, proteins and
environmental components, which are all epistatic factors
contributing to ischemic cardiomyopathy. According to the
suggested criteria for establishing positive replication a similar
population should be studied [42]. Although this work showed
significant results, a limitation of the present study is the lack of
a replication study in another related population. However, the
large number of clinically well assessed patients and controls
allowed us to exclude possible false positive results. A replica of our
study is quite demanding, owing to difficulties in enrolling another
comparable large number of patients. Nevertheless, IC patients
and controls have been recruited in a relatively large geographic
area thus avoiding possible bias related to founder effect or
population heterogeneity.
In summary, our results in a Spanish population show
suggestive evidence for the association of the mitochondrial
haplogroups H and J as risk and protection factors for ischemic
cardiomyopathy respectively, in a Spanish population. Future
analysis of the full sequenced mtDNA in these haplogroups and
their phenotypic analysis will yield additional insights towards
therapeutic targets for ischemic cardiomyopathy pathogenesis.
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